PRaG-1
Phase 2Small molecule
PRaG-1 is one of 89 small molecule programs targeting Patients With Solid Tumors. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Dexilant
TakedaPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Minipress
PfizerPreclinical
Valium
Akero TherapeuticsPreclinical
PRaG-1
SSecond Affiliated Hospital of Soochow University
Phase 2
Clomid
FerringPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Lotemax
PPharmos
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Patients With Solid Tumors1 trial
Treatment1 trial
Immune Modulation With PRaG-1 Treatment
Not yet recruiting·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT07002502·19 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PRaG-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details